#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Severe myoclonic epilepsy of infancy Deafness Cognitive disorder Mycobacterium abscessus infection Hereditary optic atrophy Pyruvate kinase deficiency anaemia Erythema multiforme Immunodeficiency common variable Desmoid tumour Nodal marginal zone B-cell lymphoma Focal segmental glomerulosclerosis Atypical haemolytic uraemic syndrome Becker's muscular dystrophy Encephalitis autoimmune Fragile X syndrome More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Life with Disease Retinitis pigmentosa – Basic Information Marfan’s syndrome – Life with Disease Testicular leiomyosarcoma Alternating hemiplegia of childhood Tuberous sclerosis complex – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Sarcoma – Treatment Hereditary motor and sensory neuropathy Wolfram syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxygen Rbp030.2 Cusatuzumab GSKVX000000034798 Desogestrel Necvax-Neo1 SGT-003 Ciprofloxacin Hydrochloride Tominersen VX-993 Ly3484356 Gsk3739937 Tofacitinib Leriglitazone Carboplatin Basimglurant MRNA-1345 Bms-986340 Benzyl Alcohol Guanabenz Acetate More therapies…

    Learn about Your Condition

    Colorectal cancer stage III Thymoma malignant Breast conserving surgery Chronic lymphocytic leukaemia Metabolic surgery Rasmussen encephalitis Neonatal asphyxia Endometrial stromal sarcoma Oesophageal cancer metastatic Gastrointestinal melanoma Thromboangiitis obliterans Pancreatic carcinoma recurrent Peptostreptococcus infection Wheezing Proteus syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Hepatobiliary cancer
    • T-cell lymphoma
    Investigated Drugs:
    • Fadraciclib
    Spain

  • Study on the Safety and Effectiveness of Durvalumab, Paclitaxel, and Drug Combinations for Patients with Metastatic Triple Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Oleclumab
    • Capivasertib
    • Datopotamab Deruxtecan
    Poland

  • Study of Adagloxad Simolenin/OBI-821, Capecitabine, and Pembrolizumab for Patients with High-Risk, Early-Stage Triple Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • OBI-821
    • Capecitabine
    • Pembrolizumab
    Poland

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer male
    • Breast cancer stage I
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Capecitabine
    • Carboplatin
    Austria Belgium France Germany Ireland Spain

  • Study on the Safety and Effectiveness of Olaparib, Ceralasertib, and AZD1775 for Patients with Metastatic Triple Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Ceralasertib
    • Olaparib
    Poland Portugal Spain

  • Study on Darolutamide and Capecitabine for Patients with Advanced Triple-Negative Androgen Receptor Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Darolutamide
    France
Previous Page
1 … 6 7 8 9 10 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!